Prostate CancerRADICALPCNCT03127631
A Study for Cardiovascular and Lifestyle Risk Factors in Prostate Cancer Patients
A study testing Nutrition, Exercise and Smoking cessation in people with Prostate Cancer and Cardiovascular Disease, run by McMaster University at 61 sites in 9 countries.
Trial summary
RADICAL PC1 is a prospective cohort study of men with a new diagnosis of prostate cancer. RADICAL PC2 is a randomized, controlled trial of a systematic approach to modifying cardiovascular and lifestyle risk factors in men with a new diagnosis of prostate cancer. Read more about this study
- Who is it for?
- Ages 45 years and older, men only
- Conditions the study is for
- Prostate Cancer, Cardiovascular Disease
- What is being tested?
- Nutrition, Exercise and Smoking cessation
- Type of treatment
- Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 5,000 participants
- Where
- 61 sitesin 9 countries
- Study dates
- 21 Oct 2015to 31 Dec 2026
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 45 years and older
- Men only
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- 1. A man with a diagnosis of prostate cancer that is either:
- new (i.e. the diagnosis was made within 1 year of the enrolment visit) or
- treated with Androgen Deprivation Therapy for the first time within 6 months prior to the enrolment visit, or
- to be treated with Androgen Deprivation Therapy for the first time within 1 month after the enrolment visit
Who cannot join
- Patients will be excluded if they fulfill any of the following:
- are unwilling to provide consent or
- are <45 years of age, or
- prostate cancer was found incidentally following cystectomy for bladder cancer
- Patients will be eligible for RADICAL PC1, but will not be eligible for RADICAL PC2 if they:
- see a cardiologist every year, or
- both take a statin and have systolic blood pressure ≤130mmHg
Trial locations and contacts
61 sites in 9 countries.
61 sites in 9 countries
Brazil25 sites
Hospital Municipal de Barueri
Barueri, São Paulo, 06463-320
Hospital Felício Rocho
Belo Horizonte, Minas Gerais, 30110-934
Faculdade de Medicina da Universidade Estadual Paulista - Campus de Botucatu - UNESP
Botucatu, São Paulo, 18618-687
Hospital Universitário São Francisco na Providência de Deus
Bragança Paulista, São Paulo, 12.916-542
Centro de Pesquisa Clínica do Brasil
Brasília, Federal District, 71625175
Sociedade Hospitalar Angelina Caron
Campina Grande do Sul, Paraná, 83.430-000
Nucleo de Pesquisa Clinica Hospital do Rocio
Campo Largo, Paraná
Centro Médico São Francisco
Curitiba, Paraná, 80810-050
Hospital de Caridade de Ijuí
Ijuí, Rio Grande do Sul, 98700-000
Fundacao Doutor Amaral Carvalho
Jaú, São Paulo, 17210080
Hospital de Clínicas de Porto Alegre
Porto Alegre, Rio Grande do Sul, 90035-903
Irmandade Da Santa Casa De Misericórdia De Porto Alegre
Porto Alegre, Rio Grande do Sul, 90050-170
Hospital Mae de Deus
Porto Alegre, Rio Grande do Sul, 90840-440
Instituto De Medicina Integral Prof. Fernando Figueira - IMIP
Recife, Pernambuco, 50.070-902
Instituto Nacional de Cardiologia
Rio de Janeiro, Rio de Janeiro, 22240-006
Fundação Faculdade Regional de Medicina de São José do Rio Preto
São José do Rio Preto, São Paulo, 15090-000
Santa Casa de São Paulo (IPITEC)
São Paulo, São Paulo, 01223-001
Hospital Alemao Oswaldo Cruz
São Paulo, São Paulo, 01327001
Beneficência Nipo-Brasileira de São Paulo. Hospital Nipo-Brasileiro
São Paulo, São Paulo, 02189-000
Núcleo de Pesquisa e Ensino da Rede São Camilo
São Paulo, São Paulo, 04014-002
Instituto do Coração do Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo and Fundação Zerbini (Incor)
São Paulo, São Paulo, 05403-000
Hospital Santa Marcelina
São Paulo, São Paulo, 08270-120
Instituto D'Or de Pesquisa e Ensino
São Paulo, São Paulo, 4543000
Universidade Federal do Triângulo Mineiro
Uberaba, Minas Gerais, 38025-260
Integral Pesquisa e Ensino
Votuporanga, São Paulo, 15501-405
Canada17 sites
St. Joseph's Healthcare
Hamilton, Ontario, L8N4A6
Juravinski Cancer Centre
Hamilton, Ontario, L8V1C3
Queen's University
Kingston, Ontario, K7L 3J7
Grand River Hospital, Grand River Regional Cancer Centre
Kitchener, Ontario, N2G 1G3
London Health Sciences Centre
London, Ontario, N6A 5W9
London Health Sciences, Victoria Hospital
London, Ontario, N6A 5W9
Hopital Maisonneuve-Rosemont
Montreal, Quebec, H1T 2M4
University Hospital of Montreal
Montreal, Quebec, H2X 0A9
McGill University
Montreal, Quebec, H3A 0G4
Jewish General Hospital
Montreal, Quebec, H3T 1E2
Niagara Health, St. Catharines Site
Niagara, Ontario, L2S 0A9
Ottawa Hospital Research Institute
Ottawa, Ontario, K1H 8L6
Laval University
Québec, Quebec, G1V 0A6
Centre Universitaire de Sherbrooke
Sherbrooke, Quebec, J1H 5N4
Sunnybrook Health Sciences Centre
Toronto, Ontario, M4N 3M5
University Health Network, Princess Margaret Cancer Centre
Toronto, Ontario, M5G 2C1
Vancouver General Hospital
Vancouver, British Columbia, V5Z 1M9
United States4 sites
Georgia Cancer Center at Augusta University
Augusta, Georgia, 30912
UT Southwestern Medical Center
Dallas, Texas, 75390
University of Kansas Medical Center
Kansas City, Kansas, 66160
University of Pennsylvania
Philadelphia, Pennsylvania, 19104
India4 sites
St. John's Medical College and Hospital
Bangalore, Karntaka, 560034
Sri shanakara cancer Hospital and Research Centre
Bengaluru, Kamataka, 560004
Kamineni Academy of Medical Sciences and Research Centre
Hyderabad, Telangana, 500068
Sri Ram Cancer & Superspeciality Centre, Mahatma Gandhi Hospital
Sītāpura, Jaipur, 302022
Australia3 sites
Royal Adelaide Hospital
Adelaide, South Australia, 5000
Flinders Medical Center
Adelaide, South Australia, 5042
Westmead Hospital
Westmead, New South Wales, 2145
Colombia3 sites
Hospital Universitario San Ignacio
Bogotá, Cundinamarca
Fundacio Valle de Lili
Cali, Valle del Cauca Department
FOSCAL
Floridablanca, Santander Department
Israel3 sites
Heart Institute - Holon Medical Center
Holon, 5840608
Rabin Medical Center
Petah Tikva, 4941492
Tel-Aviv Sourasky Medical Centre
Tel Aviv, 6423906
About this study
Official title: The Role of Androgen Deprivation Therapy In Cardiovascular Disease - A Longitudinal Prostate Cancer Study (RADICAL PC1) & A Randomized Intervention for Cardiovascular and Lifestyle Risk Factors in Prostate Cancer Patients (RADICAL PC2)
RADICAL PC1 is a prospective cohort study of men with a new diagnosis of prostate cancer. RADICAL PC2 is a randomized, controlled trial of a systematic approach to modifying cardiovascular and lifestyle risk factors in men with a new diagnosis of prostate cancer.
Read the detailed description
RADICAL PC describes two prospective studies, one of which is embedded in the other. RADICAL PC1 is a prospective cohort study of men within one year of their first diagnosis of prostate cancer, or treated with Androgen Deprivation Therapy for the first time within 6 months prior to enrollment visit, or to be treated with Androgen Deprivation Therapy for the first time within one month after the enrollment visit. Its goal will be to identify factors associated with the development of cardiovascular disease among men with prostate cancer, with a particular focus on Androgen Deprivation Therapy. RADICAL PC2 is a randomized, controlled trial embedded in RADICAL PC1. RADICAL PC2 will test a systematic approach to modifying cardiovascular and lifestyle risk factors in men within one year of their first diagnosis of prostate cancer, or treated with Androgen Deprivation Therapy for the first time within 6 months prior to enrollment visit, or to be treated with Androgen Deprivation Therapy for the first time within one month after the enrollment visit.
- Conditions
- Prostate Cancer, Cardiovascular Disease
- Being tested
- Nutrition, Exercise, Smoking cessation, Statin (such as Simvastatin, Atorvastatin, Rosuvastatin, Pravastatin), ACE inhibitor
- Keywords
- Androgen Deprivation Therapy
- Medical subject headings
- Prostatic Neoplasms, Cardiovascular Diseases
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
NutritionBehavioural
Standardized advice on healthy diet practices.
ExerciseBehavioural
Standardized advice on exercise including strength training and resistance training exercises.
Smoking cessationBehavioural
Advice to quit smoking, if applicable, and on available aids to quit smoking,
Statin (such as Simvastatin, Atorvastatin, Rosuvastatin, Pravastatin)Drug
Prescription for a low to moderate dose statin, such as simvastatin 10-40mg daily, atorvastatin 10-40mg daily, rosuvastatin 5-20mg daily or pravastatin 10-40mg daily.
ACE inhibitorDrug
Prescription for an ACE-I (preferable) or an angiotensin receptor blocker for baseline systolic blood pressure greater >130mmHg, or other blood pressure lowering medication as applicable.
| Study group | Role | What they receive |
|---|---|---|
| Randomized - Intervention | Active comparator | The intervention will consist of a systematic cardiovascular and lifestyle risk factor modification strategy, including dietary and exercise advice, advice to quit smoking, and the prescription of open-label statins, ACE-I, and other antihypertensive medications where appropriate. Receives: Behavioral: Nutrition; Behavioral: Exercise; Behavioral: Smoking cessation; Drug: Statin (such as Simvastatin, Atorvastatin, Rosuvastatin, Pravastatin); Drug: ACE inhibitor |
| Randomized - Control | No intervention | The control will consist of usual clinical care, which may include a referral to a cardiologist or internist, or the use of treatments included in the intervention as clinically indicated, if part of the treating physician's standard practice. |
What is being measured
The primary outcome is the main question the study is designed to answer.
Hierarchical composite of cardiovascular death, myocardial infarction, stroke, heart failure, cholesterol control (defined as total cholesterol ≤4mmol/L) and systolic blood pressure control (defined as systolic blood pressure ≤130mmHg).
Hierarchical composite of cardiovascular death, myocardial infarction, stroke, heart failure, cholesterol control (defined as total cholesterol ≤4mmol/L) and systolic blood pressure control (defined as systolic blood pressure ≤130mmHg).
Measured: 3-5 years
Time to the first occurrence of the composite of cardiovascular death, myocardial infarction, stroke, heart failure.
Time to the first occurrence of the composite of cardiovascular death, myocardial infarction, stroke, heart failure.
Measured: 3-5 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted25 Apr 2017
- Study start21 Oct 2015
- Primary completion31 Dec 2026 (estimated)
- Study completion31 Dec 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (3)Papers the sponsor has linked to this study.
- Other trials for Prostate CancerStudies of the same condition, open and under way.
- More trials run by McMaster UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Factorial
- Masking
- None (open label)
- Enrolment
- 5,000 participants (estimated)
Sponsor and investigators
- Lead sponsor
- McMaster University
- Sponsor type
- University, hospital or other
- Collaborators
- Prostate Cancer Canada, Canadian Cancer Society (CCS), Tolmar Inc.
- Responsible party
- Sponsor
- Investigators
- Dr. Darryl Leong, MBBs,MPH,PhD,FRACP,FESC, Study director, McMaster University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03127631
- Sponsor's protocol ID
- RADICALPC_009-001
- Acronym
- RADICALPC
- Status last verified
- Jun 2026
- First submitted
- 7 Sep 2016
- Last updated
- 2 Jul 2026
- Results posted
- No
- Data monitoring committee
- Yes
- Individual data sharing
- No
Publications
Leong DP, Higano C, Cano Garcia C, Fradet V, Siemens DR, Niazi T, Shayegan B, Guha A, Cirne F, Selvanayagam JB, Violette PD, Valle FH, Lavallee LT, Duceppe E, Anderson P, Xavier D, Lopez-Lopez JP, Villareal Trujillo N, Galapo Kann A, Piccoli RK, Mourtzakis M, Sarid D, Narasimha S, Luke PPW, Hajjar LA, Lukka H, Klotz L, Balasubramanian K, Mian R, Agapay S, Rangarajan S, Karampatos S, Ng KKH, Avezum A, Devereaux PJ, Pinthus JH; RADICAL PC Investigators. Specialist Referral for Cardiovascular Risk in Patients With Prostate Cancer: A Randomized Clinical Trial. JAMA Intern Med. 2026 Aug 30. doi: 10.1001/jamainternmed.2026.4773. Online ahead of print.
PubMed 42669035Dahan J, Pinthus J, Delouya G, Taussky D, Duceppe E, de Jesus A, Leong D. Investigation of association between clinically significant prostate cancer, obesity and platelet to-lymphocyte ratio and neutrophil -to-lymphocyte ratio. BMC Urol. 2024 Oct 16;24(1):226. doi: 10.1186/s12894-024-01617-2.
PubMed 39407194Savija N, Leong DP, Pinthus J, Karampatos S, Shayegan B, Mian R, Rangarajan S, Fradet V, de Souza RJ, Mente A, Dehghan M. Development and Comparability of a Short Food-Frequency Questionnaire to Assess Diet in Prostate Cancer Patients: The Role of Androgen Deprivation Therapy in CArdiovascular Disease - A Longitudinal Prostate Cancer Study (RADICAL PC) Substudy. Curr Dev Nutr. 2021 Aug 12;5(11):nzab106. doi: 10.1093/cdn/nzab106. eCollection 2021 Nov.
PubMed 34870071
Study at a glance
From the registry record, last updated by the sponsor on 2 Jul 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- The Role of Androgen Deprivation Therapy In Cardiovascular Disease - A Longitudinal Prostate Cancer Study (RADICAL PC1) & A Randomized Intervention for Cardiovascular and Lifestyle Risk Factors in Prostate Cancer Patients (RADICAL PC2)
- ClinicalTrials.gov ID
- NCT03127631
- Acronym / sponsor ID
- RADICALPC / RADICALPC_009-001
- Conditions
- Prostate Cancer, Cardiovascular Disease
- Keywords
- Androgen Deprivation Therapy
- Study type
- Interventional
- Recruitment status
- Active, not recruiting
- Enrolment
- 5,000 participants (estimated)
- Lead sponsor
- McMaster UniversityUniversity, hospital or other
- Collaborators
- Prostate Cancer Canada, Canadian Cancer Society (CCS), Tolmar Inc.
- Study start
- 21 Oct 2015 (actual)
- Primary completion
- 31 Dec 2026 (estimated)
- Study completion
- 31 Dec 2026 (estimated)
- First posted
- 25 Apr 2017 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
RADICAL PC1 is a prospective cohort study of men with a new diagnosis of prostate cancer. RADICAL PC2 is a randomized, controlled trial of a systematic approach to modifying cardiovascular and lifestyle risk factors in men with a new diagnosis of prostate cancer.
Detailed description
RADICAL PC describes two prospective studies, one of which is embedded in the other. RADICAL PC1 is a prospective cohort study of men within one year of their first diagnosis of prostate cancer, or treated with Androgen Deprivation Therapy for the first time within 6 months prior to enrollment visit, or to be treated with Androgen Deprivation Therapy for the first time within one month after the enrollment visit. Its goal will be to identify factors associated with the development of cardiovascular disease among men with prostate cancer, with a particular focus on Androgen Deprivation Therapy. RADICAL PC2 is a randomized, controlled trial embedded in RADICAL PC1. RADICAL PC2 will test a systematic approach to modifying cardiovascular and lifestyle risk factors in men within one year of their first diagnosis of prostate cancer, or treated with Androgen Deprivation Therapy for the first time within 6 months prior to enrollment visit, or to be treated with Androgen Deprivation Therapy for the first time within one month after the enrollment visit.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Factorial
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Randomized - Intervention | Active comparator | Behavioral: Nutrition, Behavioral: Exercise, Behavioral: Smoking cessation, Drug: Statin (such as Simvastatin, Atorvastatin, Rosuvastatin, Pravastatin), Drug: ACE inhibitorThe intervention will consist of a systematic cardiovascular and lifestyle risk factor modification strategy, including dietary and exercise advice, advice to quit smoking, and the prescription of open-label statins, ACE-I, and other antihypertensive medications where appropriate. |
| Randomized - Control | No intervention | –The control will consist of usual clinical care, which may include a referral to a cardiologist or internist, or the use of treatments included in the intervention as clinically indicated, if part of the treating physician's standard practice. |
Who may qualify
- Ages
- 45 years and older
- Sex
- Male only
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (4 listed)
- new (i.e. the diagnosis was made within 1 year of the enrolment visit) or
- treated with Androgen Deprivation Therapy for the first time within 6 months prior to the enrolment visit, or
- to be treated with Androgen Deprivation Therapy for the first time within 1 month after the enrolment visit
Key exclusion criteria (7 listed)
- Patients will be excluded if they fulfill any of the following:
- Patients will be eligible for RADICAL PC1, but will not be eligible for RADICAL PC2 if they:
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| NutritionStandardized advice on healthy diet practices. | Behavioural | Randomized - Intervention |
| ExerciseStandardized advice on exercise including strength training and resistance training exercises. | Behavioural | Randomized - Intervention |
| Smoking cessationAdvice to quit smoking, if applicable, and on available aids to quit smoking, | Behavioural | Randomized - Intervention |
| Statin (such as Simvastatin, Atorvastatin, Rosuvastatin, Pravastatin)Prescription for a low to moderate dose statin, such as simvastatin 10-40mg daily, atorvastatin 10-40mg daily, rosuvastatin 5-20mg daily or pravastatin 10-40mg daily. | Drug | Randomized - Intervention |
| ACE inhibitorPrescription for an ACE-I (preferable) or an angiotensin receptor blocker for baseline systolic blood pressure greater >130mmHg, or other blood pressure lowering medication as applicable. | Drug | Randomized - Intervention |
Primary outcome
Hierarchical composite of cardiovascular death, myocardial infarction, stroke, heart failure, cholesterol control (defined as total cholesterol ≤4mmol/L) and systolic blood pressure control (defined as systolic blood pressure ≤130mmHg).
Time frame: 3-5 years
Hierarchical composite of cardiovascular death, myocardial infarction, stroke, heart failure, cholesterol control (defined as total cholesterol ≤4mmol/L) and systolic blood pressure control (defined as systolic blood pressure ≤130mmHg).
Time to the first occurrence of the composite of cardiovascular death, myocardial infarction, stroke, heart failure.
Time frame: 3-5 years
Time to the first occurrence of the composite of cardiovascular death, myocardial infarction, stroke, heart failure.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 2 Jul 2026.
- Derived from this study: PubMed 42669035Leong DP, Higano C, Cano Garcia C, Fradet V, Siemens DR, Niazi T, Shayegan B, Guha A, Cirne F, Selvanayagam JB, Violette PD, Valle FH, Lavallee LT, Duceppe E, Anderson P, Xavier D, Lopez-Lopez JP, Villareal Trujillo N, Galapo Kann A, Piccoli RK, Mourtzakis M, Sarid D, Narasimha S, Luke PPW, Hajjar LA, Lukka H, Klotz L, Balasubramanian K, Mian R, Agapay S, Rangarajan S, Karampatos S, Ng KKH, Avezum A, Devereaux PJ, Pinthus JH; RADICAL PC Investigators. Specialist Referral for Cardiovascular Risk in Patients With Prostate Cancer: A Randomized Clinical Trial. JAMA Intern Med. 2026 Aug 30. doi: 10.1001/jamainternmed.2026.4773. Online ahead of print.
- Derived from this study: PubMed 39407194Dahan J, Pinthus J, Delouya G, Taussky D, Duceppe E, de Jesus A, Leong D. Investigation of association between clinically significant prostate cancer, obesity and platelet to-lymphocyte ratio and neutrophil -to-lymphocyte ratio. BMC Urol. 2024 Oct 16;24(1):226. doi: 10.1186/s12894-024-01617-2.
- Derived from this study: PubMed 34870071Savija N, Leong DP, Pinthus J, Karampatos S, Shayegan B, Mian R, Rangarajan S, Fradet V, de Souza RJ, Mente A, Dehghan M. Development and Comparability of a Short Food-Frequency Questionnaire to Assess Diet in Prostate Cancer Patients: The Role of Androgen Deprivation Therapy in CArdiovascular Disease - A Longitudinal Prostate Cancer Study (RADICAL PC) Substudy. Curr Dev Nutr. 2021 Aug 12;5(11):nzab106. doi: 10.1093/cdn/nzab106. eCollection 2021 Nov.
- Individual participant dataSharing planned: No
Related trials for Prostate Cancer
Active, not recruiting
Streamlined Geriatric and Oncological Evaluation Based On IC Technology
Breast Cancer, Comorbidities and Coexisting Conditions
Active, not recruitingObservational study
MRI Fusion Biopsy vs. Micro-Ultrasound Guided Biopsy
Prostate Cancer
Enrolling by invitationObservational study
Natural History Study of Early Life Exposures in Agriculture (ELEA)
Prostate Cancer, Leukemia
Not yet recruitingPhase 1/2
STAR0602 With Nivolumab in Non Small Cell Lung Cancer and in Metastatic Castrate-Resistant Prostate Cancer, and STAR0602 Alone in Thymic Carcinoma
NSCLC, Non-Small Cell Lung Cancer
Recruiting
Rehabilitation and Sex Therapy to Optimize Recovery After Prostate Cancer Treatment
Prostate Cancer, Urinary Incontinence
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Dr. Darryl Leong, MBBs,MPH,PhD,FRACP,FESC study director
McMaster University
61 sites in 9 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Nutrition, Exercise and Smoking cessation in people with Prostate Cancer and Cardiovascular Disease, run by McMaster University at 61 sites in 9 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: under way, not looking for participants, as of the sponsor's last update on 2 Jul 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 61 sites in Brazil, Canada, United States, India, Australia and 4 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Hierarchical composite of cardiovascular death, myocardial infarction, stroke, heart failure, cholesterol control (defined as total cholesterol ≤4mmol/L) and systolic blood pressure control (defined as systolic blood pressure ≤130mmHg). (time frame: 3-5 years). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT03127631, which also lists 3 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 2 Jul 2026.